A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer

NCT03866980 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

164

Enrollment

INDUSTRY

Sponsor class

Stopped corporate strategy adjustment

Conditions

Lung Cancer Non-small Cell Stage IV

Interventions

BIOLOGICAL: AK105
DRUG: carboplatin
DRUG: pemetrexed
DRUG: placebo
DRUG: Anlotinib

Sponsor

Akeso

Collaborators

[object Object]